CN107648468A - A kind of Chinese medicine composition for treating COPD and its application - Google Patents
A kind of Chinese medicine composition for treating COPD and its application Download PDFInfo
- Publication number
- CN107648468A CN107648468A CN201711118569.8A CN201711118569A CN107648468A CN 107648468 A CN107648468 A CN 107648468A CN 201711118569 A CN201711118569 A CN 201711118569A CN 107648468 A CN107648468 A CN 107648468A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition for treating COPD, described Chinese medicine composition is made up of following bulk drug：The Radix Astragali, Radix Codonopsis, Semen Cuscutae, prepared rhizome of rehmannia, psoralea corylifolia, sealwort, dried orange peel, fritillaria, thorny elaeagnus leaf, Ligusticum wallichii, radix glycyrrhizae.The present invention also provides the application of the Chinese medicine composition.Its advantage is shown：The Radix Astragali, Radix Codonopsis, prepared rhizome of rehmannia, sealwort are invigorated the lung and the kidney in side, and Semen Cuscutae tonifying kidney and benefiting sperm, psoralea corylifolia is tonified the kidney and support yang, gas of receiving is relievingd asthma, dried orange peel eliminating the phlegmization drink, bulbus fritillariae cirrhosae moistening lung for removing phlegm cough-relieving, thorny elaeagnus leaf astringe the lung relieving asthma, preventing phlegm from forming and stopping coughing, Ligusticum wallichii is promoting blood circulation and removing blood stasis, radix glycyrrhizae coordinating the drug actions of a prescription.All medicines share, making lung kidney, the phlegm water stasis of blood disappears altogether with mending.The Chinese medicine composition of the present invention is experimentally verified that, can effectively treat COPD.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, is a kind of Chinese traditional medicine composition for treating COPD specifically
Thing and its application.
Background technology
COPD (COPD) be it is a kind of it is common characterized by continuation flow limitation can prevent and
The disease for the treatment of, flow limitation are usually progressivity, and the chronic inflammatory of toxic granular or gas is reacted with air flue and lungs and increased
Strong correlation.Any patient for having expiratory dyspnea, chronic cough or expectoration and COPD risk factors exposes histories, is considered as COPD
Diagnosis.This disease mainly involves lungs, but may also lead to the ill effect outside systemic or lung.Serious infringement the elderly
The health of group, and in progress sexual development.Acute exacerbation and complication influence the overall order of severity of patient.COPD early stages
Symptom is slight, only may on a small quantity cough and cough up phlegm, repeatedly to disease progression, normal Complicated with Spontaneous Pneumothorax, breathing after acute exacerbation
Exhaustion, chronic cor pulmonale etc..Therefore, to COPD patient, we should accomplish early discovery, early treatment, it is therefore intended that mitigate society
It can bear, and improve life in patients.
COPD is a kind of disease with flow limitation feature, its flow limitation is not fully reversible, in carry out sexual development, with
Lung reacts relevant to the abnormal inflammatory of pernicious gas or deleterious particle.Mainly with smoking, air pollution, RRTI
It is relevant etc. factor.In recent years, from COPD inherent cause, signal transduction, inflammatory mediator, airway remodeling, cilium-mucus system and
Function of receptors etc. deeply discloses this sick pathogenesis, has deepened the understanding to COPD essence.
Traditional Chinese medicine thinks that COPD attacks lungs for a long time by exopathogen more, and lung declares respectful malfunction, and then lung qi virtual loss, pectoral qi are given birth to long
Change deficiency, clear gas can not be transported to the whole body, and foul smell is difficult to excrete, and heap soil or fertilizer over and around the roots is stagnant in the heart, cause lung qi turgor, it is impossible to hold back drop.Lung is
The master of QI, the kidney being the root of QI, patient's condition is deep, causes kidney qi feeble and exhausted, the not main gas of lung, the failure of the kidney in receiving air, causes qi deficiency of lung and kidney eventually, blood is not
Freely, gather and be that phlegm is the stasis of blood, sthenia symptoms caused by asthenia meets sense exopathogen priming volt phlegm hemostasis, blocks lung qi, and it is respectful that lung loses a surname, and gives birth to cough, phlegm, asthma
All diseases.So in COPD any stages, qi deficiency of lung and kidney is the most basic pathological change of this disease, and phlegm wet blood stasis is important pathology production
Thing and pathogenic factor.Therefore, when COPD enters stationary phase, face card must be declined with lung kidney deficiency for this, so that phlegm is turbid, water drink, blood stasis
For mark, take nourishing lung and kidney, strengthen the body resistance to consolidate the constitution, dispel and drunk with phlegmization, be promoting blood circulation and removing blood stasis, so as to promote healthy tendency gradually to recover, with control
Seizure of disease.
Chinese patent literature CN101530493A discloses a kind of pharmaceutical composition for treating respiratory disease, effectively into
Point raw material be：1) tonifying middle-Jiao and Qi, strengthening spleen and tonifying lung medicine, it is selected from：Radix Codonopsis, the Radix Astragali, ginseng, radix pseudostellariae, American Ginseng；2) enriching yin is mended
Blood, kidney-nourishing essence medicine, it is selected from：Cultivated land, radix rehmanniae recen, Radix Angelicae Sinensis；3) tonify the liver and kidney, consolidate Dingchuan medicine, it is selected from：Dogwood fruit, He Shou
Crow, the fruit of Chinese magnoliavine, dried human placenta, gekko；4) relieving exterior syndrome and dispelling cold, medicine of freeinging lung and relieving asthma, it is selected from：Ephedra, gingko；5) heat-clearing and damp-drying drug, rush down
Fiery antidote, it is selected from：Radix scutellariae, cymose buckwheat rhizome, the root bark of white mulberry；6) regulating qi-flowing for strengthening spleen, eliminating dampness and eliminating phlegm medicine, it is selected from：Dried orange peel, rascal, trifoliate orange
Shell, Exocarpium Citri Rubrum；7) moistening lung to lower qi, stopping coughing and removing phlegm medicine, it is selected from：Aster, the tuber of stemona, tussilago；8) clearing heat and cooling blood, drug for invigorating blood circulation and eliminating stasis,
It is selected from：The radix paeoniae rubrathe, the red sage root, root tuber of aromatic turmeric；With 9) radix glycyrrhizae.But on a kind of Chinese medicine for treating COPD of the present invention
Composition and its application yet there are no report.
The content of the invention
The purpose of the present invention is to be directed to deficiency of the prior art, there is provided a kind of Chinese medicine for treating COPD
Composition.
Second object of the present invention is to provide a kind of application for the Chinese medicine composition for treating COPD.
To achieve the above object, the present invention adopts the technical scheme that：A kind of Chinese medicine for treating COPD
Composition, described Chinese medicine composition are made up of the bulk drug of following parts by weight：Radix Astragali 10-20 parts, Radix Codonopsis 7-11 parts, Semen Cuscutae
10-20 parts, prepared rhizome of rehmannia 7-11 parts, psoralea corylifolia 7-11 parts, sealwort 10-20 parts, dried orange peel 7-11 parts, fritillaria 7-11 parts, thorny elaeagnus leaf
10-20 parts, Ligusticum wallichii 7-11 parts, radix glycyrrhizae 5-7 parts.
Described Chinese medicine composition is made up of the bulk drug of following parts by weight：Radix Astragali 13-17 parts, Radix Codonopsis 8-10 parts, Tu silks
Sub- 13-17 parts, prepared rhizome of rehmannia 8-10 parts, psoralea corylifolia 8-10 parts, sealwort 13-17 parts, dried orange peel 8-10 parts, fritillaria 8-10 parts, thorny elaeagnus
Leaf 13-17 parts, Ligusticum wallichii 6-10 parts, radix glycyrrhizae 5.5-6.5 parts.
Described Chinese medicine composition is made up of the bulk drug of following parts by weight：15 parts of the Radix Astragali, 9 parts of Radix Codonopsis, 15 parts of Semen Cuscutae,
9 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 15 parts of sealwort, 9 parts of dried orange peel, 9 parts of fritillaria, 15 parts of thorny elaeagnus leaf, 9 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae.
Described Chinese medicine composition is used in combination with fluticasone propionate, ambroxol.
Described fluticasone propionate 50mg containing salmeterol, fluticasone propionate 500mg.
Described ambroxol is ambroxol hydrochloride sustained-release tablet.
To realize above-mentioned second purpose, the present invention adopts the technical scheme that：Described Chinese medicine composition is controlled in preparation
Treat the application in the medicine of COPD.
Described pharmaceutical dosage form is granule, dispersible tablet, capsule, pill, oral liquid or powder.
The invention has the advantages that：
1st, the Radix Astragali, Radix Codonopsis, prepared rhizome of rehmannia, sealwort are invigorated the lung and the kidney in side, and Semen Cuscutae tonifying kidney and benefiting sperm, psoralea corylifolia is tonified the kidney and support yang, received
Gas is relievingd asthma, dried orange peel eliminating the phlegmization drink, bulbus fritillariae cirrhosae moistening lung for removing phlegm cough-relieving, thorny elaeagnus leaf astringe the lung relieving asthma, preventing phlegm from forming and stopping coughing, Ligusticum wallichii promoting blood circulationization
The stasis of blood, radix glycyrrhizae coordinating the drug actions of a prescription.All medicines share, making lung kidney, the phlegm water stasis of blood disappears altogether with mending.
2nd, Chinese medicine composition of the invention is experimentally verified that, can effectively treat COPD.
3rd, clinical test shows：Treatment group is superior to compare in terms of clinical efficacy, tcm syndrome curative effect, PFT improvement
Group (P ＜ 0.05).Coordinate treatment by Chinese herbs on the basis of prompting western medicine routine treatment, its curative effect is better than simple western medical treatment, Chinese medicine ginseng
Stilbene consolidate soup treatment COPD stationary phase syndrome of qi deficiency of lung and kidney patients there is good advantage, can effective symptom management, alleviate clinical condition
Shape, improve patients ' life quality, moreover it is possible to improve pulmonary ventilation situation, further genralrlization and further investigation are done on clinic.
Embodiment
Embodiment provided by the invention is elaborated with reference to embodiment.
The Chinese medicine composition of embodiment 1
15 parts of the Radix Astragali, 9 parts of Radix Codonopsis, 15 parts of Semen Cuscutae, 9 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 15 parts of sealwort, 9 parts of dried orange peel, fritillaria
9 parts, 15 parts of thorny elaeagnus leaf, 9 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 2
10 parts of the Radix Astragali, 7 parts of Radix Codonopsis, 20 parts of Semen Cuscutae, 7 parts of prepared rhizome of rehmannia, 11 parts of psoralea corylifolia, 10 parts of sealwort, 8 parts of dried orange peel, shellfish
Female 7 parts, 10 parts of thorny elaeagnus leaf, 11 parts of Ligusticum wallichii, 5.5 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 3
11 parts of the Radix Astragali, 8 parts of Radix Codonopsis, 19 parts of Semen Cuscutae, 9 parts of prepared rhizome of rehmannia, 7 parts of psoralea corylifolia, 11 parts of sealwort, 10 parts of dried orange peel, shellfish
Female 7.5 parts, 20 parts of thorny elaeagnus leaf, 10.5 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 4
12 parts of the Radix Astragali, 9 parts of Radix Codonopsis, 18 parts of Semen Cuscutae, 11 parts of prepared rhizome of rehmannia, 10.5 parts of psoralea corylifolia, 12 parts of sealwort, 9 parts of dried orange peel,
8 parts of fritillaria, 11 parts of thorny elaeagnus leaf, 10 parts of Ligusticum wallichii, 6.5 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 5
13 parts of the Radix Astragali, 10 parts of Radix Codonopsis, 17 parts of Semen Cuscutae, 8 parts of prepared rhizome of rehmannia, 7.5 parts of psoralea corylifolia, 13 parts of sealwort, dried orange peel 8.5
Part, 8.5 parts of fritillaria, 19 parts of thorny elaeagnus leaf, 9.5 parts of Ligusticum wallichii, 5.5 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 6
14 parts of the Radix Astragali, 11 parts of Radix Codonopsis, 16 parts of Semen Cuscutae, 9 parts of prepared rhizome of rehmannia, 10 parts of psoralea corylifolia, 14 parts of sealwort, 9 parts of dried orange peel, shellfish
Female 9 parts, 12 parts of thorny elaeagnus leaf, 9 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 7
15 parts of the Radix Astragali, 7.5 parts of Radix Codonopsis, 15 parts of Semen Cuscutae, 10 parts of prepared rhizome of rehmannia, 8 parts of psoralea corylifolia, 15 parts of sealwort, dried orange peel 9.5
Part, 9 parts of fritillaria, 18 parts of thorny elaeagnus leaf, 8.5 parts of Ligusticum wallichii, 6.5 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 8
16 parts of the Radix Astragali, 8.5 parts of Radix Codonopsis, 14 parts of Semen Cuscutae, 8.5 parts of prepared rhizome of rehmannia, 9.5 parts of psoralea corylifolia, 16 parts of sealwort, dried orange peel 11
Part, 9 parts of fritillaria, 13 parts of thorny elaeagnus leaf, 8 parts of Ligusticum wallichii, 7 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 9
17 parts of the Radix Astragali, 9 parts of Radix Codonopsis, 13 parts of Semen Cuscutae, 9 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 17 parts of sealwort, 9 parts of dried orange peel, fritillaria
9.5 parts, 17 parts of thorny elaeagnus leaf, 7.5 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 10
18 parts of the Radix Astragali, 9.5 parts of Radix Codonopsis, 12 parts of Semen Cuscutae, 9.5 parts of prepared rhizome of rehmannia, 8.5 parts of psoralea corylifolia, 18 parts of sealwort, dried orange peel 7
Part, 10 parts of fritillaria, 14 parts of thorny elaeagnus leaf, 7 parts of Ligusticum wallichii, 5 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 11
19 parts of the Radix Astragali, 10.5 parts of Radix Codonopsis, 11 parts of Semen Cuscutae, 7.5 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 19 parts of sealwort, dried orange peel
10.5 parts, 10.5 parts of fritillaria, 16 parts of thorny elaeagnus leaf, 9 parts of Ligusticum wallichii, 5 parts of radix glycyrrhizae
The Chinese medicine composition of embodiment 12
20 parts of the Radix Astragali, 9 parts of Radix Codonopsis, 10 parts of Semen Cuscutae, 10.5 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 20 parts of sealwort, dried orange peel 7.5
Part, 11 parts of fritillaria, 15 parts of thorny elaeagnus leaf, 9 parts of Ligusticum wallichii, 7 parts of radix glycyrrhizae
The granule of embodiment 13
Embodiment 1-12 Chinese medicine composition, add water to cook 3 times, merging filtrate, be concentrated into relative density be 1.1 it is clear
Cream.Clear cream adds ethanol, stands 24 hours, filtration, reclaims ethanol, is concentrated into the thick paste that relative density is 1.2.Thick paste is sprayed
Mist is dried, and get dry extract fine powder.Dry cream fine powder is added into dextrin, is well mixed, pelletizes according to a conventional method, dries, granule is made.
The dispersible tablet of embodiment 14
Embodiment 1-12 Chinese medicine composition, add water to cook 3 times, merging filtrate, be concentrated into relative density be 1.1 it is clear
Cream.Clear cream is spray-dried, and obtains dry cream fine powder.Dry cream fine powder is well mixed with sodium carboxymethyl starch, microcrystalline cellulose,
Pelletize, dry according to a conventional method, add magnesium stearate, silica, mix, tabletting according to a conventional method, dispersible tablet is made.
The capsule of embodiment 15
Embodiment 1-12 Chinese medicine composition, add water to cook 3 times, merging filtrate, be concentrated into relative density be 1.15 it is clear
Cream.Clear cream is spray-dried, and obtains dry cream fine powder.Magnesium stearate, talcum powder are added, mixes, adds according to a conventional method hollow
Capsule, capsule is made.
The pill of embodiment 16
Embodiment 1-12 Chinese medicine composition, add water to cook 3 times, merging filtrate, be concentrated into relative density be 1.18 it is clear
Cream.Clear cream is spray-dried, and obtains fine powder.Suitable quantity of water or/and yellow rice wine are added, water-bindered pill agent is made.Or add ethanol in proper amount and
Softwood is made in soybean oil, softwood micropill pellet processing machine pill, dries, and sieving, micropill is made.Or using polyethylene glycol as matrix, two
Methyl-silicone oil is condensate liquid, dripping pelletization, pill is made.
The oral liquid of embodiment 17
Embodiment 1-12 Chinese medicine composition, add water to cook 3 times, merging filtrate, be concentrated into relative density be 1.1 it is clear
Cream.Clear cream adds ethanol, stands 24 hours, filtration, reclaims ethanol, is concentrated into the thick paste that relative density is 1.2.According to a conventional method
Take stevioside to be dissolved in pure water, add sodium benzoate, purified water, be well mixed with thick paste, oral liquid is made.
The powder of embodiment 18
Embodiment 1-12 Chinese medicine composition, RHIZOMA FAGOPYRI CYMOSI, the bighead atractylodes rhizome, Radix Angelicae Sinensis are respectively fed to be cut into flakelet in slicer, then
It is sent into pulverizer and is ground into smalls, other bulk drugs is directly ground into smalls with pulverizer.Sieving, then will be thin after sieving
Powder input mixing and blending machine fully mixes, and obtains powder.
The soup of embodiment 19
Embodiment 1-12 Chinese medicine composition adds water to cook, and obtains soup.
Comparative example 1
15 parts of Radix Codonopsis, 15 parts of the moxibustion Radix Astragali, 10 parts of the bighead atractylodes rhizome, windproof 10 parts, 12 parts of Chinese yam, 10 parts of lily, 15 parts of the tuber of stemona, dried orange peel
6 parts, 6 parts of moxibustion radix glycyrrhizae
Comparative example 2
15 parts of the Radix Astragali, 9 parts of Radix Codonopsis
Comparative example 3
15 parts of Semen Cuscutae, 9 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 15 parts of sealwort, 9 parts of dried orange peel, 9 parts of fritillaria, 15 parts of thorny elaeagnus leaf,
9 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae
Comparative example 4
Aminophylline
The animal experiment of embodiment 20
First, materials and methods
1st, animal and packet
Cleaning grade male SD rat 90,180~200g of body weight.It is randomly divided into 9 groups, every group 10.9 groups respectively normal
1 group of group, model group, embodiment (crude drug amount 2.2gkg-1), 5 groups of (crude drug amount 2.2gkg of embodiment-1), 10 groups of embodiment
(crude drug amount 2.2gkg-1), 1 group of (crude drug amount 2.2gkg of comparative example-1), 2 groups of (crude drug amount 2.2gkg of comparative example-1), contrast
3 groups of (crude drug amount 2.2gkg of example-1), 4 groups of (aminophylline 0.054mgkg of comparative example-1)。
2nd, test method
In the 1st, 14 day 10% chloraldurate ip anesthetized rat, neck median incision 2cm, tracheae, micro syringe are separated
From tracheae to lung direction instillation lipopolysaccharides, (sterile saline is configured to 1gL-1), the 2nd~30 day (except the 14th day) will be big
Mouse, which is put into smoke from cigarette, smokes 1 hour/time, and 2 times/day, COPD models are made.Each group presses 10mlkg-1Dosage ig is administered, 1 time/
My god, totally 30 days.Last dose is drawn materials after 30 minutes.
Normal group is in the 1st, 14 day with method tracheal instillation physiological saline not sootiness.
3rd, Testing index
3.1 pulmonary function detection
By rat with 10% chloraldurate (0.35gkg-1) anesthesia, longitudinal incision skin of neck, exposure tracheae, in ring-type
One inverted " t " type otch of cartilage incision, insertion are connected with the trachea cannula of three-way cock, one end connection animal respirator, one end
Connect signal acquiring system measurement breathing index.Determine the 0.3rd second forced expiratory volume (FEV 0.3), forced vital capacity
(FVC), the parameter value such as FEV0.3/FVC, PEF.
3.2 serum cytokines
IL-6, TNF-α are determined, PFT rat has been surveyed and has opened abdominal cavity, abdominal aortic blood, 4 DEG C of low-temperature centrifugations rapidly
(3000rpm), take -70 DEG C of supernatant to freeze, detected by kit illustration method.
2nd, result
1st, each group pulmonary function detection result is as shown in table 1.
The each group pulmonary function detection result of table 1
2nd, each group blood serum IL-6, TNF-α result are as shown in table 2.
The each group blood serum IL-6 of table 2, TNF-α result
The clinical test of embodiment 21
1 clinical data
1.1 general information
All patients are all from August, the 2015 division of respiratory disease outpatient service of in August, -2016 of the Jing'an District hospital of traditional Chinese hospital, include 70 altogether,
It is randomly divided into control group and treatment group.Control group 35, man 19, female 16, average age 58.97 ± 9.25 years old, average disease
Journey 10.2 ± 7.809 years；Treatment group 35, man 21, female 14, average age 61.74 ± 9.053 years old, average course of disease 10.91
± 6.270 years；Two groups of patient ages, sex, courses of disease are not statistically significant (P ＞ 0.05), have comparativity.
1.2 case selection
1.2.1 Western medicine diagnostic criteria：
Formulated with Department of Medical Administration of the Ministry of Public Health《COPD diagnosis and treatment specification (version in 2011)》For foundation, COPD's
Diagnosis should determine according to comprehensive analysis such as the risk factors such as smoking, clinical symptoms, sign and pulmonary function tests.Not exclusively may be used
Inverse flow limitation is the necessary requirement of COPD diagnosis.FEV1/FVC ＜ 70% can be identified as endless after suction bronchodilatation medicine
Full reversible airflow limitation.Small number of patients has no the symptoms such as cough, expectoration, obvious shortness of breath, is only found in pulmonary function test
FEV1/FVC ＜ 70%, except after other diseases, also diagnosable is COPD.Stationary phase patient shows as coughing, coughed up phlegm, shortness of breath
It is lighter etc. symptom stabilization or symptom.
1.2.2 tcm diagnosis standard
With reference to version in 2002《New Chinese medicine guideline of clinical investigations》、《The dialectical specification of tcm syndrome》Deng relevant lung in book
Syndrome of deficiency of kidney qi standard formulation.Cardinal symptom has asthma to lose heart, dynamic then breathe heavily very, and fright due to decicincy of qi sound is low, and Mian Se Koushi are white, spontaneous perspiration easy catching a cold, is afraid of
It is cold, soreness and weakness of waist and knees, clear abundant urine, pale tongue, deep,thready and forceless pulse.
1.2.3 inclusive criteria
Meet COPD diagnostic criteria, be by stages stationary phase, the PFT order of severity belong to light moderate (FEV1/FVC ＜ 70%,
The predicted values of FEV1 ＜ 80%) patient；Chinese medical discrimination category syndrome of qi deficiency of lung and kidney person；After treatment, symptom obtains Acute Exacerbation Period substantially
To alleviation, or only cough, cough up phlegm on a small quantity；Age is in 40~75 one full year of life；And sign informed consent form.
1.2.4 exclusion standard
Can cause asthma or dyspneic Other diseases patient, as cystic fibrosis, DPB or
Bronchiolitis obliterans etc.；Merge the primary diseases such as severe cardiac, liver, kidney and hemopoietic system, internal system, or AIDS
Disease, tumour, psychiatric patient；In COPD patients with acute exacerbation.
2 methods
2.1 treatment method
Control group：Give fluticasone propionate (salmeterol 50mg, fluticasone propionate 500mg, Glaxo Operations UK
Limited, authentication code：H20090242) 1 suction every time, 1 time a day.Doxofylline piece (Heilungkiang good fortune and Hua Xing pharmacy group
Limited company, authentication code：H19991048, specification 0.2g/ piece) 1 tablet once, 2 times a day.Ambroxol hydrochloride sustained-release tablet
(Shi Yao groups Ou Yi medicine companies, authentication code：H20080643, specification 75mg/ piece) 1 tablet once, 1 time a day.Treatment group is compareing
Soup is consolidated on the basis of group plus with from plan ginseng stilbene, Chinese medicine ginseng stilbene consolidates decoction of medicinal ingredients thing composition：The Radix Astragali 15, Radix Codonopsis 9, Semen Cuscutae 15, cultivated land
Huang 9, psoralea corylifolia 9, sealwort 15, dried orange peel 9, fritillaria 9, thorny elaeagnus leaf 15, Ligusticum wallichii 9, radix glycyrrhizae 6) 1 dose/day of Chinese medicine, decocting point is sooner or later
Warmly take twice.Two groups of patient procedures are 6 months.
2.2 observation index
Cardinal symptom (cough, cough up phlegm, shortness of breath), the sign (rale) of pretherapy and post-treatment patient is recorded, Chinese medicine syndrome integral becomes
Change situation, and lung function tests：Forced expiratory volume in one second (FEV1), first second amount are recorded than forced vital capacity (FEV1/
) and forced vital capacity (FVC) FVC%.
2.3 statistical analysis
Using the statistical softwares of SPSS 21.0 analyze, data information withRepresenting, normal distribution data is examined using t,
Non-Gaussian Distribution data is examined using t'.One-dimensional order data uses rank test.P ＜ 0.05 represent that difference has statistics meaning
Justice.
3 results
3.1 curative effect determinate standard references《New Chinese medicine guideline of clinical investigations》Formulate.
Cardinal symptom curative effect determinate standard：Cough, cough up phlegm, shortness of breath, rale individual event symptom and sign curative effect.Clinic control：
Symptom disappears after treatment；It is effective：Symptom is clearly better after treatment, from severe to slight；Effectively：Symptom take a favorable turn after treatment, from
Severe is to moderate or from moderate to slight；It is invalid：Symptom without improvement or aggravates after treatment.
Tcm syndrome curative effect determinate standard：Tcm syndrome curative effect=(before treatment syndrome integral-syndrome integral after treatment)/control
Syndrome integral × 100% before treatment.Clinic control：Symptom, sign disappear or basic disappearance, syndrome integral reduce >=90%；It is effective：
Symptom, sign are obviously improved, and syndrome integral reduces >=70%；Effectively：Symptom, sign have taken a turn for the better, and syndrome integral reduction >=
30%；It is invalid：Symptom, sign are not improved, or even are aggravated, and syndrome integral reduces ＜ 30%.
3.2 result
Two groups of clinic cardinal symptom therapeutic evaluatioies are relatively shown in Table 3, and the total effective rate for the treatment of group is 94.3%, and control group is
74.3%.Comparison between two groups shows that difference has significant difference (P ＜ 0.05).The patient for the treatment of group can be prompted by ginseng stilbene
After consolidating soup treatment, it is better than control group in clinical symptoms improvement.
2 groups of case clinic cardinal symptom therapeutic evaluatioies are compared after table 3 is treated
Note：Through Mann-Whirney U rank tests, Z=2.282, P=0.022, P ＜ 0.05.
Two groups of tcm syndrome curative effects are relatively shown in Table 4, and the total effective rate for the treatment of group is 97.1%, and control group is 77.1%.2
Comparison between group shows that difference has significant difference (P ＜ 0.0001).The patient for the treatment of group can be prompted to pass through the side of invigorating the lung and the kidney
After therapy treatment, control group is substantially better than in the improvement of tcm syndrome symptom.
The tcm syndrome therapeutic evaluation of 2 groups of cases is compared after table 4 is treated
Note：Through Mann-Whirney U rank tests, Z=5.629, P ＜ 0.0001.
Two groups of PFTs are relatively shown in Table 5, the FEV before the treatment of two groups of each 35 patients1%pre, FVC, FEV1/ FVC% is passed through
Marked difference (P ＞ 0.05) is there are no after statistical analysis, there is comparativity.After treatment, statistical result prompting, two groups are controlled
Itself compare FEV before and after treating1%pre, FVC, FEV1/ FVC%, which declines, is respectively provided with statistical significance (P ＜ 0.05).By 6
After the treatment of the moon, FEV between two groups1%pre, FEV1/ FVC% more statistically significant (P ＜ 0.05), FVC compares nothing between two groups
Obvious significant difference.Prompt two groups of FEV1%pre, FEV1/ FVC% can have a certain degree of improvement (P ＜ 0.01), and its
Delay Forced expiratory volume in one second (FEV1%pre) decline and improve first second amount and be better than control than the effect of lung capacity
Group (P ＜ 0.05).
Table 5 treat after 2 groups of case PFT ventilation ratios compared with
Note：Through paired t-test, with this group before treatment,▲P<0.05；Through independent samples t-test, compare after being treated with control group
Compared with,★p<0.05。
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the inventive method is not departed from, can also make some improvement and supplement, and these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (8)
1. a kind of Chinese medicine composition for treating COPD, it is characterised in that described Chinese medicine composition is by following
The bulk drug of parts by weight is made：Radix Astragali 10-20 parts, Radix Codonopsis 7-11 parts, Semen Cuscutae 10-20 parts, prepared rhizome of rehmannia 7-11 parts, psoralea corylifolia 7-
11 parts, sealwort 10-20 parts, dried orange peel 7-11 parts, fritillaria 7-11 parts, thorny elaeagnus leaf 10-20 parts, Ligusticum wallichii 7-11 parts, radix glycyrrhizae 5-7 parts.
2. Chinese medicine composition according to claim 1, it is characterised in that described Chinese medicine composition is by following parts by weight
Bulk drug is made：Radix Astragali 13-17 parts, Radix Codonopsis 8-10 parts, Semen Cuscutae 13-17 parts, prepared rhizome of rehmannia 8-10 parts, psoralea corylifolia 8-10 parts, Huang
Smart 13-17 parts, dried orange peel 8-10 parts, fritillaria 8-10 parts, thorny elaeagnus leaf 13-17 parts, Ligusticum wallichii 6-10 parts, radix glycyrrhizae 5.5-6.5 parts.
3. Chinese medicine composition according to claim 1, it is characterised in that described Chinese medicine composition is by following parts by weight
Bulk drug is made：15 parts of the Radix Astragali, 9 parts of Radix Codonopsis, 15 parts of Semen Cuscutae, 9 parts of prepared rhizome of rehmannia, 9 parts of psoralea corylifolia, 15 parts of sealwort, 9 parts of dried orange peel,
9 parts of fritillaria, 15 parts of thorny elaeagnus leaf, 9 parts of Ligusticum wallichii, 6 parts of radix glycyrrhizae.
4. according to any described Chinese medicine compositions of claim 1-3, it is characterised in that described Chinese medicine composition and Shu Li
Repeatedly, ambroxol is used in combination.
5. Chinese medicine composition according to claim 4, it is characterised in that described fluticasone propionate 50mg containing salmeterol, third
Sour fluticasone 500mg.
6. Chinese medicine composition according to claim 4, it is characterised in that described ambroxol is ambroxol hydrochloride sustained-release
Piece.
7. according to any described Chinese medicine compositions of claim 1-3 in the medicine for treating COPD is prepared
Using.
8. application according to claim 7, it is characterised in that described pharmaceutical dosage form is granule, dispersible tablet, capsule
Agent, pill, oral liquid or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711118569.8A CN107648468B (en) | 2017-11-14 | 2017-11-14 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711118569.8A CN107648468B (en) | 2017-11-14 | 2017-11-14 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107648468A true CN107648468A (en) | 2018-02-02 |
| CN107648468B CN107648468B (en) | 2020-08-25 |
Family
ID=61120432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711118569.8A Active CN107648468B (en) | 2017-11-14 | 2017-11-14 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648468B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111588757A (en) * | 2019-06-21 | 2020-08-28 | 中日友好医院 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof |
| CN115814022A (en) * | 2022-12-13 | 2023-03-21 | 上海市中医医院 | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with asthma prevention and/or treatment effects |
| CN115998818A (en) * | 2022-09-23 | 2023-04-25 | 上海雷允上药业有限公司 | New application of Dongtian vinca paste, pharmaceutical composition and application |
| CN116370563A (en) * | 2023-05-22 | 2023-07-04 | 长春中医药大学 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058865A (en) * | 2010-12-28 | 2011-05-18 | 邹德奇 | Traditional Chinese medicinal preparation for treating stable-phase chronic obstructive pulmonary disease |
-
2017
- 2017-11-14 CN CN201711118569.8A patent/CN107648468B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058865A (en) * | 2010-12-28 | 2011-05-18 | 邹德奇 | Traditional Chinese medicinal preparation for treating stable-phase chronic obstructive pulmonary disease |
Non-Patent Citations (1)
| Title |
|---|
| 简亚梅等: "沙美特罗/丙酸氟替卡松联合盐酸氨溴索对慢性阻塞性肺疾病患者肺功能和血气指标的影响", 《中国当代医药》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111588757A (en) * | 2019-06-21 | 2020-08-28 | 中日友好医院 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof |
| CN115998818A (en) * | 2022-09-23 | 2023-04-25 | 上海雷允上药业有限公司 | New application of Dongtian vinca paste, pharmaceutical composition and application |
| CN115998818B (en) * | 2022-09-23 | 2024-05-14 | 上海雷允上药业有限公司 | New application of Dongtian vinca paste, pharmaceutical composition and application |
| CN115814022A (en) * | 2022-12-13 | 2023-03-21 | 上海市中医医院 | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with asthma prevention and/or treatment effects |
| CN116370563A (en) * | 2023-05-22 | 2023-07-04 | 长春中医药大学 | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107648468B (en) | 2020-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107648468A (en) | A kind of Chinese medicine composition for treating COPD and its application | |
| CN104491672A (en) | Traditional Chinese medicine preparation for treating chronic tracheitis and preparation method thereof | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN103479932B (en) | One treats bronchitic Chinese medicine composition and preparation method thereof | |
| CN103028093B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary emphysema and preparation method of traditional Chinese medicine composition | |
| CN102861199A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux disease and preparation method | |
| CN104257977A (en) | Traditional Chinese medicine preparation for treating liver-stomach disharmony type chronic superficial gastritis | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN102716372B (en) | Traditional Chinese medicine composition for curing chronic cough, and preparation method and usage thereof | |
| CN104547859A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating chronic tracheitis | |
| CN115624586B (en) | Traditional Chinese medicine composition for treating hormone-dependent asthma and application thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN109771632A (en) | A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease | |
| CN114732889B (en) | Traditional Chinese medicine composition and traditional Chinese medicine oral preparation for treating phlegm turbidity and lung obstruction in acute attack stage of bronchial asthma | |
| CN104491637B (en) | It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application | |
| CN104127544B (en) | The application in preparing medicine of Murraya tetramera Huang and extract thereof | |
| CN103417827B (en) | Oral traditional Chinese medicine for treating chronic bronchitis and preparation method thereof | |
| CN108310195A (en) | A kind of Chinese medicine composition and its preparation method and application for treating idiopathic pulmonary fibrosis | |
| CN102716371B (en) | Traditional Chinese medicine composition for curing chronic cough as well as preparation method and usages thereof | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN104721386B (en) | A kind of Traditional Chinese medicine external patch and preparation method thereof for treating asthenic cold type cough and asthma | |
| CN104606465A (en) | Medicine for treating acute pharyngitis and preparation method for medicine | |
| CN104116906B (en) | A kind of Chinese medicine composition and preparation method thereof for treating cough with lung heat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |